This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



I

X = N or CH,

R^1, R^3 = independently of one another H, OH, OA, CN, Hal, COR^4 or CH_2R^4,

R^2 = ~~H,~~ an optionally mono- or poly-Hal-substituted, linear or branched alkyl moiety having 1-6 C atoms, or an alkaryl, alkheteroaryl, or heteroaryl moiety,

R^4 = OH, OA, NH_2, NHB or NB_2,

A, B = independently of one another alkyl having 1-6 C atoms,

m = 2, 3, 4, 5 or 6 and

n = 0, 1, 2, 3 or 4,

~~and~~or physiologically acceptable salts, ~~derivatives,~~ solvates ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1 in which

X = N,

R^1, R^3 = independently of one another CN, COR^4 or CH_2R^4,

R^2 = a linear or branched alkyl having 1-6 C atoms, alkaryl, alkheteroaryl, or heteroaryl,

R^4 = OH, NH_2, NHB or NB_2,

A, B = independently of one another alkyl having 1-6 C atoms,

m = 4 and

n = 0,

and physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~

a. 5-{4-[4-(5-cyano-1-methyl-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

b. 5-{4-[4-(5-cyano-1-ethyl-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

c. 5-{4-[4-(5-cyano-1-isopropyl-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

d. 5-{4-[4-(1-benzyl-5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

e. 5-{4-[4-(5-cyano-1-propyl-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

f. 5-{4-[4-(5-cyano-1-pyridin-2-ylmethyl-1H-indol-3-yl)butyl]piperazin-1-yl}-benzofuran-2-carboxamide

g. 5-{4-[4-(5-cyano-1-phenethyl-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

4. (Currently Amended) Process for the preparation of the compounds of the formula I, ~~characterised in that~~comprising

a) reacting a compound of the formula II, in which R^1 and m have the meanings indicated in Claim 1 and Y is a halogen or is an alcohol provided with a protecting group known to the person skilled in the art,



II

~~is reacted~~ with a compound of the formula III, in which R^2 has the meanings indicated in Claim 1 and Z represents a leaving group ~~known to the person skilled in the art, such as, for example, p-tosyl, trifluoromethanesulfonyl, methanesulfonyl, benzenesulfonyl, Br, Cl or I~~

III

and

b) ~~in that the~~reacting a compound of the formula IV



IV

obtained in accordance with a) ~~is reacted~~ with a compound of the formula V or a salt thereof, in which R^3, X and n have the meanings indicated in Claim 1,



V

in a solvent, optionally with addition of base, at the boiling point of the solvent,

or

c) ~~in that the~~converting a base of a compound of the formula I ~~is converted~~ into one of its salts by treatment with an acid.

5. (Canceled)

6. (Currently Amended) Pharmaceutical composition comprising at least one compound according to Claim 1 and/or physiologically acceptable salts, ~~derivatives,~~ solvates ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios, and a pharmaceutically acceptable carrier.

7. (Original) Pharmaceutical composition, according to Claim 6 comprising further excipients and/or adjuvants.

8. (Currently Amended) Pharmaceutical composition comprising at least one compound according to Claim 1 and/or physiologically acceptable salts, ~~derivatives,~~ solvates ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

9. (Currently Amended) Process for the preparation of a pharmaceutical composition, ~~characterised in that~~comprising bringing a compound according to Claim 1 and/or one of its physiologically acceptable salts, ~~derivatives,~~ solvates ~~and~~or stereoisomers, including mixtures thereof in all ratios, ~~is brought~~ into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.

10. (Canceled)

11. (Currently Amended) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament~~A method for the treatment of diseases associated with the serotonin receptor and/or serotonin reuptake, comprising administering to a host in need thereof an effective amount of a compound according to Claim 1 and/or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament as~~A method of achieving an anxiolytic, antidepressant, neuroleptic and/or antihypertonic effect and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, ~~such as bulimia or IBS,~~ and/or sexual dysfunctions, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament~~A method for the treatment of psychoses, schizophrenia, schizo-affective psychosis, cyclothymia, epilepsy, cramps, depression ~~(sub-types of severe depression and cyclothymic depression)~~, pathogenic anxiety states ~~(sub-types of panic attacks with or without agoraphobia)~~, superexcitation, hyperactivity, stress illnesses, post-traumatic stress disorders, sleeping disorders, narcolepsy, cyclic manic depression, attention disorders in children and youths, severe developmental disorders, ~~and~~ disorders of social ~~behaviour~~behavior with mental retardation, obsessive-compulsive disorders in

the narrower (OCD) and broader sense (OCSD), addiction disorders, disorders in nutrient uptake or eating disorders, ~~for example bulimia, obesity or anorexia nervosa, in particular~~ irritable bowel syndrome (IBS), fibromyalgia, ~~and~~ psychiatric symptoms in senile dementia ~~and~~or Alzheimer's-type dementia, cognitive impairments ~~(learning and memory disorders), in particular age-dependent memory disorders, dementia,~~ tardive dyskinesia, neurodegenerative diseases, ~~such as Parkinson's disease,~~ Alzheimer's disease, Huntington's disease, lathyrism, amyotrophic lateral sclerosis, Lewy bodies dementia, Tourette's syndrome, sexual dysfunctions, premenstrual syndrome, acromegaly, hypogonadism, secondary amenorrhoea, undesired puerperal lactation, extrapyramidal motor disorders, ~~for the treatment of~~ side effects arising in the treatment of extrapyramidal motor disorders with conventional anti-Parkinson's medicaments, ~~and of~~ extrapyramidal symptoms ~~(EPS)~~, tension states, side effects of hypertonia treatment induced by neuroleptics ~~(for example with α-methyldopa) or~~ for the prophylaxis, treatment and control of cerebral infarctions ~~(apoplexia cerebri), such as strokes and cerebral ischaemia,~~ or for the treatment of pain, ~~in particular chronic pain,~~ migraine, CNS trauma, hypoglycaemia, asthma, glaucoma, cytomegaly ~~and for the treatment of other~~ degenerative retinal diseases, incontinence, tinnitus, or ~~for the treatment of~~ loss of hearing induced by aminoglycoside antibiotics, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) A ~~Set~~ ~~(kit)~~ consisting of separate packs of

a) an effective amount of a compound according to Claim 1 and/or physiologically acceptable salts, ~~derivatives,~~ solvates ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios, and

b) an effective amount of a further medicament active ingredient.